{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T13:01:11Z","timestamp":1793970071128,"version":"4.8.0"},"reference-count":170,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T00:00:00Z","timestamp":1741737600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T00:00:00Z","timestamp":1741737600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clinic Rev Allerg Immunol"],"DOI":"10.1007\/s12016-025-09042-5","type":"journal-article","created":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T19:29:01Z","timestamp":1741807741000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["The Role of IL-17 in Systemic Autoinflammatory Diseases: Mechanisms and Therapeutic Perspectives"],"prefix":"10.1007","volume":"68","author":[{"given":"Jingyuan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,12]]},"reference":[{"key":"9042_CR1","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1038\/ni1467","volume":"8","author":"EV Acosta-Rodriguez","year":"2007","unstructured":"Acosta-Rodriguez EV, Rivino L, Geginat J, Jarrossay D, Gattorno M, Lanzavecchia A et al (2007) Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nat Immunol 8:639\u2013646. https:\/\/doi.org\/10.1038\/ni1467","journal-title":"Nat Immunol"},{"key":"9042_CR2","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41577-022-00746-9","volume":"23","author":"KHG Mills","year":"2023","unstructured":"Mills KHG (2023) IL-17 and IL-17-producing cells in protection versus pathology. Nat Rev Immunol 23:38\u201354. https:\/\/doi.org\/10.1038\/s41577-022-00746-9","journal-title":"Nat Rev Immunol"},{"key":"9042_CR3","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S0065-2776(08)00605-6","volume":"99","author":"DB O'Quinn","year":"2008","unstructured":"O\u2019Quinn DB, Palmer MT, Lee YK, Weaver CT (2008) Emergence of the Th17 pathway and its role in host defense. Adv Immunol 99:115\u2013163. https:\/\/doi.org\/10.1016\/S0065-2776(08)00605-6","journal-title":"Adv Immunol"},{"key":"9042_CR4","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1111\/prd.12083","volume":"69","author":"C Zenobia","year":"2000","unstructured":"Zenobia C (2000) Hajishengallis G (2015) Basic biology and role of interleukin-17 in immunity and inflammation. Periodontol 69:142\u2013159. https:\/\/doi.org\/10.1111\/prd.12083","journal-title":"Periodontol"},{"key":"9042_CR5","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1111\/j.1365-2567.2009.03240.x","volume":"129","author":"RM Onishi","year":"2010","unstructured":"Onishi RM, Gaffen SL (2010) Interleukin-17 and its target genes: mechanisms of interleukin-17 function in disease. Immunology 129:311\u2013321. https:\/\/doi.org\/10.1111\/j.1365-2567.2009.03240.x","journal-title":"Immunology"},{"key":"9042_CR6","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/nature14282","volume":"522","author":"SB Coffelt","year":"2015","unstructured":"Coffelt SB, Kersten K, Doornebal CW, Weiden J, Vrijland K, Hau CS et al (2015) IL-17-producing gammadelta T cells and neutrophils conspire to promote breast cancer metastasis. Nature 522:345\u2013348. https:\/\/doi.org\/10.1038\/nature14282","journal-title":"Nature"},{"key":"9042_CR7","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/s41392-023-01620-3","volume":"8","author":"L Huangfu","year":"2023","unstructured":"Huangfu L, Li R, Huang Y, Wang S (2023) The IL-17 family in diseases: from bench to bedside. Signal Transduct Target Ther 8:402. https:\/\/doi.org\/10.1038\/s41392-023-01620-3","journal-title":"Signal Transduct Target Ther"},{"key":"9042_CR8","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","volume":"373","author":"D Baeten","year":"2015","unstructured":"Baeten D, Sieper J, Braun J, Baraliakos X, Dougados M, Emery P et al (2015) Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis. N Engl J Med 373:2534\u20132548. https:\/\/doi.org\/10.1056\/NEJMoa1505066","journal-title":"N Engl J Med"},{"key":"9042_CR9","doi-asserted-by":"publisher","unstructured":"Fragoulis GE, Siebert S (2020) Treatment strategies in axial spondyloarthritis: what, when and how? Rheumatology (Oxford).59:iv79-iv89. https:\/\/doi.org\/10.1093\/rheumatology\/keaa435","DOI":"10.1093\/rheumatology\/keaa435"},{"key":"9042_CR10","doi-asserted-by":"publisher","first-page":"102421","DOI":"10.1016\/j.jaut.2020.102421","volume":"109","author":"J Krainer","year":"2020","unstructured":"Krainer J, Siebenhandl S, Weinhausel A (2020) Systemic autoinflammatory diseases. J Autoimmun 109:102421. https:\/\/doi.org\/10.1016\/j.jaut.2020.102421","journal-title":"J Autoimmun"},{"key":"9042_CR11","doi-asserted-by":"publisher","unstructured":"Galozzi P, Negm O, Bindoli S, Tighe P, Sfriso P, Punzi L (2022) A Pro-Inflammatory Signature Constitutively Activated in Monogenic Autoinflammatory Diseases. Int J Mol Sci.23. https:\/\/doi.org\/10.3390\/ijms23031828","DOI":"10.3390\/ijms23031828"},{"key":"9042_CR12","doi-asserted-by":"publisher","unstructured":"Magnol M, Couvaras L, Degboe Y, Delabesse E, Bulai-Livideanu C, Ruyssen-Witrand A, et al. (2021) VEXAS syndrome in a patient with previous spondyloarthritis with a favourable response to intravenous immunoglobulin and anti-IL17 therapy. Rheumatology (Oxford).60:e314-e315. https:\/\/doi.org\/10.1093\/rheumatology\/keab211","DOI":"10.1093\/rheumatology\/keab211"},{"key":"9042_CR13","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/gene.2013.6","volume":"14","author":"A Ovadia","year":"2013","unstructured":"Ovadia A, Livneh A, Feld O, Ben-Zvi I, Kukuy E, Kivity S et al (2013) T helper 17 polarization in familial Mediterranean fever. Genes Immun 14:212\u2013216. https:\/\/doi.org\/10.1038\/gene.2013.6","journal-title":"Genes Immun"},{"key":"9042_CR14","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1136\/annrheumdis-2020-219137","volume":"80","author":"DM Schwartz","year":"2021","unstructured":"Schwartz DM, Kitakule MM, Dizon BL, Gutierrez-Huerta C, Blackstone SA, Burma AM et al (2021) Systematic evaluation of nine monogenic autoinflammatory diseases reveals common and disease-specific correlations with allergy-associated features. Ann Rheum Dis 80:788\u2013795. https:\/\/doi.org\/10.1136\/annrheumdis-2020-219137","journal-title":"Ann Rheum Dis"},{"key":"9042_CR15","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/nri2586","volume":"9","author":"SL Gaffen","year":"2009","unstructured":"Gaffen SL (2009) Structure and signalling in the IL-17 receptor family. Nat Rev Immunol 9:556\u2013567. https:\/\/doi.org\/10.1038\/nri2586","journal-title":"Nat Rev Immunol"},{"key":"9042_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaut.2015.04.006","volume":"60","author":"N Isailovic","year":"2015","unstructured":"Isailovic N, Daigo K, Mantovani A, Selmi C (2015) Interleukin-17 and innate immunity in infections and chronic inflammation. J Autoimmun 60:1\u201311. https:\/\/doi.org\/10.1016\/j.jaut.2015.04.006","journal-title":"J Autoimmun"},{"key":"9042_CR17","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1084\/jem.20061551","volume":"204","author":"ML Michel","year":"2007","unstructured":"Michel ML, Keller AC, Paget C, Fujio M, Trottein F, Savage PB et al (2007) Identification of an IL-17-producing NK1.1(neg) iNKT cell population involved in airway neutrophilia. J Exp Med 204:995\u20131001. https:\/\/doi.org\/10.1084\/jem.20061551","journal-title":"J Exp Med"},{"key":"9042_CR18","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/nri2800","volume":"10","author":"DJ Cua","year":"2010","unstructured":"Cua DJ, Tato CM (2010) Innate IL-17-producing cells: the sentinels of the immune system. Nat Rev Immunol 10:479\u2013489. https:\/\/doi.org\/10.1038\/nri2800","journal-title":"Nat Rev Immunol"},{"key":"9042_CR19","doi-asserted-by":"publisher","first-page":"2993","DOI":"10.1182\/blood-2011-01-329268","volume":"118","author":"P Milpied","year":"2011","unstructured":"Milpied P, Massot B, Renand A, Diem S, Herbelin A, Leite-de-Moraes M et al (2011) IL-17-producing invariant NKT cells in lymphoid organs are recent thymic emigrants identified by neuropilin-1 expression. Blood 118:2993\u20133002. https:\/\/doi.org\/10.1182\/blood-2011-01-329268","journal-title":"Blood"},{"key":"9042_CR20","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1136\/annrheumdis-2014-206323","volume":"74","author":"F Ciccia","year":"2015","unstructured":"Ciccia F, Guggino G, Rizzo A, Saieva L, Peralta S, Giardina A et al (2015) Type 3 innate lymphoid cells producing IL-17 and IL-22 are expanded in the gut, in the peripheral blood, synovial fluid and bone marrow of patients with ankylosing spondylitis. Ann Rheum Dis 74:1739\u20131747. https:\/\/doi.org\/10.1136\/annrheumdis-2014-206323","journal-title":"Ann Rheum Dis"},{"key":"9042_CR21","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1182\/blood.2018892752","volume":"134","author":"C Carmona-Rivera","year":"2019","unstructured":"Carmona-Rivera C, Khaznadar SS, Shwin KW, Irizarry-Caro JA, O\u2019Neil LJ, Liu Y et al (2019) Deficiency of adenosine deaminase 2 triggers adenosine-mediated NETosis and TNF production in patients with DADA2. Blood 134:395\u2013406. https:\/\/doi.org\/10.1182\/blood.2018892752","journal-title":"Blood"},{"key":"9042_CR22","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.1056\/NEJMoa2026834","volume":"383","author":"DB Beck","year":"2020","unstructured":"Beck DB, Ferrada MA, Sikora KA, Ombrello AK, Collins JC, Pei W et al (2020) Somatic Mutations in UBA1 and Severe Adult-Onset Autoinflammatory Disease. N Engl J Med 383:2628\u20132638. https:\/\/doi.org\/10.1056\/NEJMoa2026834","journal-title":"N Engl J Med"},{"key":"9042_CR23","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1136\/annrheumdis-2018-213746","volume":"77","author":"P Mistry","year":"2018","unstructured":"Mistry P, Carmona-Rivera C, Ombrello AK, Hoffmann P, Seto NL, Jones A et al (2018) Dysregulated neutrophil responses and neutrophil extracellular trap formation and degradation in PAPA syndrome. Ann Rheum Dis 77:1825\u20131833. https:\/\/doi.org\/10.1136\/annrheumdis-2018-213746","journal-title":"Ann Rheum Dis"},{"key":"9042_CR24","doi-asserted-by":"publisher","first-page":"4479","DOI":"10.4049\/jimmunol.0901942","volume":"184","author":"S Shahrara","year":"2010","unstructured":"Shahrara S, Pickens SR, Mandelin AM 2nd, Karpus WJ, Huang Q, Kolls JK et al (2010) IL-17-mediated monocyte migration occurs partially through CC chemokine ligand 2\/monocyte chemoattractant protein-1 induction. J Immunol 184:4479\u20134487. https:\/\/doi.org\/10.4049\/jimmunol.0901942","journal-title":"J Immunol"},{"key":"9042_CR25","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.it.2017.01.006","volume":"38","author":"N Amatya","year":"2017","unstructured":"Amatya N, Garg AV, Gaffen SL (2017) IL-17 Signaling: The Yin and the Yang. Trends Immunol 38:310\u2013322. https:\/\/doi.org\/10.1016\/j.it.2017.01.006","journal-title":"Trends Immunol"},{"key":"9042_CR26","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.immuni.2011.02.012","volume":"34","author":"Y Iwakura","year":"2011","unstructured":"Iwakura Y, Ishigame H, Saijo S, Nakae S (2011) Functional specialization of interleukin-17 family members. Immunity 34:149\u2013162. https:\/\/doi.org\/10.1016\/j.immuni.2011.02.012","journal-title":"Immunity"},{"key":"9042_CR27","doi-asserted-by":"crossref","unstructured":"Jovanovic DV, Di Battista JA, Martel-Pelletier J, Jolicoeur FC, He Y, Zhang M, et al. (1998) IL-17 stimulates the production and expression of proinflammatory cytokines, IL-beta and TNF-alpha, by human macrophages. Journal of Immunology (Baltimore, Md : 1950).160:3513\u20133521. https:\/\/pubmed.ncbi.nlm.nih.gov\/9531313","DOI":"10.4049\/jimmunol.160.7.3513"},{"key":"9042_CR28","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/s41584-019-0294-7","volume":"15","author":"J Sieper","year":"2019","unstructured":"Sieper J, Poddubnyy D, Miossec P (2019) The IL-23-IL-17 pathway as a therapeutic target in axial spondyloarthritis. Nat Rev Rheumatol 15:747\u2013757. https:\/\/doi.org\/10.1038\/s41584-019-0294-7","journal-title":"Nat Rev Rheumatol"},{"key":"9042_CR29","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1038\/s41584-018-0091-8","volume":"14","author":"EM Gravallese","year":"2018","unstructured":"Gravallese EM, Schett G (2018) Effects of the IL-23-IL-17 pathway on bone in spondyloarthritis. Nat Rev Rheumatol 14:631\u2013640. https:\/\/doi.org\/10.1038\/s41584-018-0091-8","journal-title":"Nat Rev Rheumatol"},{"key":"9042_CR30","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.molimm.2018.12.024","volume":"107","author":"J Deng","year":"2019","unstructured":"Deng J, Yu XQ, Wang PH (2019) Inflammasome activation and Th17 responses. Mol Immunol 107:142\u2013164. https:\/\/doi.org\/10.1016\/j.molimm.2018.12.024","journal-title":"Mol Immunol"},{"key":"9042_CR31","doi-asserted-by":"publisher","first-page":"3829","DOI":"10.4049\/jimmunol.1401633","volume":"194","author":"M Larena","year":"2015","unstructured":"Larena M, Holmgren J, Lebens M, Terrinoni M, Lundgren A (2015) Cholera toxin, and the related nontoxic adjuvants mmCT and dmLT, promote human Th17 responses via cyclic AMP-protein kinase A and inflammasome-dependent IL-1 signaling. J Immunol 194:3829\u20133839. https:\/\/doi.org\/10.4049\/jimmunol.1401633","journal-title":"J Immunol"},{"key":"9042_CR32","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1189\/jlb.1012543","volume":"93","author":"KH Mills","year":"2013","unstructured":"Mills KH, Dungan LS, Jones SA, Harris J (2013) The role of inflammasome-derived IL-1 in driving IL-17 responses. J Leukoc Biol 93:489\u2013497. https:\/\/doi.org\/10.1189\/jlb.1012543","journal-title":"J Leukoc Biol"},{"key":"9042_CR33","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1002\/eji.200425677","volume":"35","author":"S Vanden Eijnden","year":"2005","unstructured":"Vanden Eijnden S, Goriely S, De Wit D, Willems F, Goldman M (2005) IL-23 up-regulates IL-10 and induces IL-17 synthesis by polyclonally activated naive T cells in human. Eur J Immunol 35:469\u2013475. https:\/\/doi.org\/10.1002\/eji.200425677","journal-title":"Eur J Immunol"},{"key":"9042_CR34","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1084\/jem.20041257","volume":"201","author":"CL Langrish","year":"2005","unstructured":"Langrish CL, Chen Y, Blumenschein WM, Mattson J, Basham B, Sedgwick JD et al (2005) IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 201:233\u2013240. https:\/\/doi.org\/10.1084\/jem.20041257","journal-title":"J Exp Med"},{"key":"9042_CR35","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/nri3707","volume":"14","author":"SL Gaffen","year":"2014","unstructured":"Gaffen SL, Jain R, Garg AV, Cua DJ (2014) The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing. Nat Rev Immunol 14:585\u2013600. https:\/\/doi.org\/10.1038\/nri3707","journal-title":"Nat Rev Immunol"},{"key":"9042_CR36","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1007\/s10875-021-01161-w","volume":"42","author":"EA Caseley","year":"2022","unstructured":"Caseley EA, Lara-Reyna S, Poulter JA, Topping J, Carter C, Nadat F et al (2022) An Atypical Autoinflammatory Disease Due to an LRR Domain NLRP3 Mutation Enhancing Binding to NEK7. J Clin Immunol 42:158\u2013170. https:\/\/doi.org\/10.1007\/s10875-021-01161-w","journal-title":"J Clin Immunol"},{"key":"9042_CR37","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/j.immuni.2009.04.012","volume":"30","author":"G Meng","year":"2009","unstructured":"Meng G, Zhang F, Fuss I, Kitani A, Strober W (2009) A mutation in the Nlrp3 gene causing inflammasome hyperactivation potentiates Th17 cell-dominant immune responses. Immunity 30:860\u2013874. https:\/\/doi.org\/10.1016\/j.immuni.2009.04.012","journal-title":"Immunity"},{"key":"9042_CR38","unstructured":"Haznedaroglu S, Ozturk MA, Sancak B, Goker B, Onat AM, Bukan N et al (2005) Serum interleukin 17 and interleukin 18 levels in familial Mediterranean fever. Clin Exp Rheumatol.23:S77\u201380, https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/16273770"},{"key":"9042_CR39","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1159\/000508077","volume":"57","author":"H Wang","year":"2020","unstructured":"Wang H, Wei G, Cheng S, Wang D, Ma J, Xin S (2020) Circulatory CD4-Positive T-Lymphocyte Imbalance Mediated by Homocysteine-Induced AIM2 and NLRP1 Inflammasome Upregulation and Activation Is Associated with Human Abdominal Aortic Aneurysm. J Vasc Res 57:276\u2013290. https:\/\/doi.org\/10.1159\/000508077","journal-title":"J Vasc Res"},{"key":"9042_CR40","doi-asserted-by":"publisher","unstructured":"Varela Martins T, Silva de Melo BM, Toller-Kawahisa JE, da Silva GVL, Anibal Silva CE, Paiva IM, et al. (2024) The DNA sensor AIM2 mediates psoriasiform inflammation by inducing type 3 immunity. JCI insight.9. https:\/\/doi.org\/10.1172\/jci.insight.171894","DOI":"10.1172\/jci.insight.171894"},{"key":"9042_CR41","doi-asserted-by":"publisher","first-page":"e0175153","DOI":"10.1371\/journal.pone.0175153","volume":"12","author":"S Zwicker","year":"2017","unstructured":"Zwicker S, Hattinger E, Bureik D, Batycka-Baran A, Schmidt A, Gerber PA et al (2017) Th17 micro-milieu regulates NLRP1-dependent caspase-5 activity in skin autoinflammation. PLoS ONE 12:e0175153. https:\/\/doi.org\/10.1371\/journal.pone.0175153","journal-title":"PLoS ONE"},{"key":"9042_CR42","doi-asserted-by":"publisher","first-page":"eabg8145","DOI":"10.1126\/scisignal.abg8145","volume":"17","author":"JR Coombs","year":"2024","unstructured":"Coombs JR, Zamoshnikova A, Holley CL, Maddugoda MP, Teo DET, Chauvin C et al (2024) NLRP12 interacts with NLRP3 to block the activation of the human NLRP3 inflammasome. Sci Signal 17:eabg8145. https:\/\/doi.org\/10.1126\/scisignal.abg8145","journal-title":"Sci Signal"},{"key":"9042_CR43","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/mi.2015.80","volume":"9","author":"S Cai","year":"2016","unstructured":"Cai S, Batra S, Del Piero F, Jeyaseelan S (2016) NLRP12 modulates host defense through IL-17A-CXCL1 axis. Mucosal Immunol 9:503\u2013514. https:\/\/doi.org\/10.1038\/mi.2015.80","journal-title":"Mucosal Immunol"},{"key":"9042_CR44","doi-asserted-by":"publisher","first-page":"10907","DOI":"10.1096\/fj.202000795R","volume":"34","author":"DS Prado","year":"2020","unstructured":"Prado DS, Veras FP, Ferreira RG, Damasceno LEA, Melo PH, Zamboni DS et al (2020) NLRP12 controls arthritis severity by acting as a checkpoint inhibitor of Th17 cell differentiation. FASEB J 34:10907\u201310919. https:\/\/doi.org\/10.1096\/fj.202000795R","journal-title":"FASEB J"},{"key":"9042_CR45","doi-asserted-by":"publisher","first-page":"109176","DOI":"10.1016\/j.celrep.2021.109176","volume":"35","author":"FRC Costa","year":"2021","unstructured":"Costa FRC, Leite JA, Rassi DM, da Silva JF, Elias-Oliveira J, Guimaraes JB et al (2021) NLRP1 acts as a negative regulator of Th17 cell programming in mice and humans with autoimmune diabetes. Cell Rep 35:109176. https:\/\/doi.org\/10.1016\/j.celrep.2021.109176","journal-title":"Cell Rep"},{"key":"9042_CR46","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.immuni.2007.08.013","volume":"27","author":"AJ van Beelen","year":"2007","unstructured":"van Beelen AJ, Zelinkova Z, Taanman-Kueter EW, Muller FJ, Hommes DW, Zaat SA et al (2007) Stimulation of the intracellular bacterial sensor NOD2 programs dendritic cells to promote interleukin-17 production in human memory T cells. Immunity 27:660\u2013669. https:\/\/doi.org\/10.1016\/j.immuni.2007.08.013","journal-title":"Immunity"},{"key":"9042_CR47","doi-asserted-by":"publisher","first-page":"5406","DOI":"10.1038\/s41467-020-18961-0","volume":"11","author":"RJ Napier","year":"2020","unstructured":"Napier RJ, Lee EJ, Davey MP, Vance EE, Furtado JM, Snow PE et al (2020) T cell-intrinsic role for Nod2 in protection against Th17-mediated uveitis. Nat Commun 11:5406. https:\/\/doi.org\/10.1038\/s41467-020-18961-0","journal-title":"Nat Commun"},{"key":"9042_CR48","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.4049\/jimmunol.1700507","volume":"201","author":"RJ Napier","year":"2018","unstructured":"Napier RJ, Lee EJ, Vance EE, Snow PE, Samson KA, Dawson CE et al (2018) Nod2 Deficiency Augments Th17 Responses and Exacerbates Autoimmune Arthritis. J Immunol 201:1889\u20131898. https:\/\/doi.org\/10.4049\/jimmunol.1700507","journal-title":"J Immunol"},{"key":"9042_CR49","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.jaci.2012.02.004","volume":"129","author":"CE Janssen","year":"2012","unstructured":"Janssen CE, Rose CD, De Hertogh G, Martin TM, Bader Meunier B, Cimaz R et al (2012) Morphologic and immunohistochemical characterization of granulomas in the nucleotide oligomerization domain 2-related disorders Blau syndrome and Crohn disease. J Allergy Clin Immunol 129:1076\u20131084. https:\/\/doi.org\/10.1016\/j.jaci.2012.02.004","journal-title":"J Allergy Clin Immunol"},{"key":"9042_CR50","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1093\/rheumatology\/ket384","volume":"53","author":"Q Yao","year":"2014","unstructured":"Yao Q, Myles J, Shen B, McDonald C (2014) NOD2-associated autoinflammatory disease: an exploratory study of its pathogenesis. Rheumatology (Oxford) 53:958\u2013960. https:\/\/doi.org\/10.1093\/rheumatology\/ket384","journal-title":"Rheumatology (Oxford)"},{"key":"9042_CR51","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.1084\/jem.20061775","volume":"203","author":"K Sato","year":"2006","unstructured":"Sato K, Suematsu A, Okamoto K, Yamaguchi A, Morishita Y, Kadono Y et al (2006) Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med 203:2673\u20132682. https:\/\/doi.org\/10.1084\/jem.20061775","journal-title":"J Exp Med"},{"key":"9042_CR52","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1172\/JCI65054","volume":"123","author":"J Kikuta","year":"2013","unstructured":"Kikuta J, Wada Y, Kowada T, Wang Z, Sun-Wada GH, Nishiyama I et al (2013) Dynamic visualization of RANKL and Th17-mediated osteoclast function. J Clin Invest 123:866\u2013873. https:\/\/doi.org\/10.1172\/JCI65054","journal-title":"J Clin Invest"},{"key":"9042_CR53","doi-asserted-by":"crossref","unstructured":"Katz Y, Nadiv O, Beer Y (2001) Interleukin-17 enhances tumor necrosis factor alpha-induced synthesis of interleukins 1,6, and 8 in skin and synovial fibroblasts: a possible role as a \"fine-tuning cytokine\" in inflammation processes. Arthritis and Rheumatism.44:2176\u20132184. https:\/\/pubmed.ncbi.nlm.nih.gov\/11592383","DOI":"10.1002\/1529-0131(200109)44:9<2176::AID-ART371>3.0.CO;2-4"},{"key":"9042_CR54","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1002\/art.10509","volume":"46","author":"E Aganna","year":"2002","unstructured":"Aganna E, Martinon F, Hawkins PN, Ross JB, Swan DC, Booth DR et al (2002) Association of mutations in the NALP3\/CIAS1\/PYPAF1 gene with a broad phenotype including recurrent fever, cold sensitivity, sensorineural deafness, and AA amyloidosis. Arthritis Rheum 46:2445\u20132452. https:\/\/doi.org\/10.1002\/art.10509","journal-title":"Arthritis Rheum"},{"key":"9042_CR55","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/ng756","volume":"29","author":"HM Hoffman","year":"2001","unstructured":"Hoffman HM, Mueller JL, Broide DH, Wanderer AA, Kolodner RD (2001) Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. Nat Genet 29:301\u2013305. https:\/\/doi.org\/10.1038\/ng756","journal-title":"Nat Genet"},{"key":"9042_CR56","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3109\/03009748709102523","volume":"16","author":"AM Prieur","year":"2009","unstructured":"Prieur AM, Griscelli C, Lampert F, Truckenbrodt H, Guggenheim MA, Lovell DJ et al (2009) A Chronic, Infantile, Neurological, Cutaneous and Articular (CINCA) Syndrome. A Specific Entity Analysed in 30 Patients. Scand J Rheumatol 16:57\u201368. https:\/\/doi.org\/10.3109\/03009748709102523","journal-title":"Scand J Rheumatol"},{"key":"9042_CR57","doi-asserted-by":"publisher","first-page":"e20014","DOI":"10.1371\/journal.pone.0020014","volume":"6","author":"D Lasiglie","year":"2011","unstructured":"Lasiglie D, Traggiai E, Federici S, Alessio M, Buoncompagni A, Accogli A et al (2011) Role of IL-1 beta in the development of human T(H)17 cells: lesson from NLPR3 mutated patients. PLoS ONE 6:e20014. https:\/\/doi.org\/10.1371\/journal.pone.0020014","journal-title":"PLoS ONE"},{"key":"9042_CR58","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1038\/ni1496","volume":"8","author":"EV Acosta-Rodriguez","year":"2007","unstructured":"Acosta-Rodriguez EV, Napolitani G, Lanzavecchia A, Sallusto F (2007) Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. Nat Immunol 8:942\u2013949. https:\/\/doi.org\/10.1038\/ni1496","journal-title":"Nat Immunol"},{"key":"9042_CR59","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.immuni.2008.03.004","volume":"28","author":"W Ouyang","year":"2008","unstructured":"Ouyang W, Kolls JK, Zheng Y (2008) The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity 28:454\u2013467. https:\/\/doi.org\/10.1016\/j.immuni.2008.03.004","journal-title":"Immunity"},{"key":"9042_CR60","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1111\/j.1365-2133.2010.09978.x","volume":"163","author":"A Yamauchi","year":"2010","unstructured":"Yamauchi A, Iwata H, Ohnishi H, Teramoto T, Kondo N, Seishima M (2010) Interleukin-17 expression in the urticarial rash of familial cold autoinflammatory syndrome: a case report. Br J Dermatol 163:1351\u20131353. https:\/\/doi.org\/10.1111\/j.1365-2133.2010.09978.x","journal-title":"Br J Dermatol"},{"key":"9042_CR61","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/s0092-8674(00)80539-5","volume":"90","author":"International FMF Consortium","year":"1997","unstructured":"International FMF Consortium (1997) Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. The International FMF Consortium. Cell 90:797\u2013807. https:\/\/doi.org\/10.1016\/s0092-8674(00)80539-5","journal-title":"The International FMF Consortium. Cell"},{"key":"9042_CR62","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/ng0997-25","volume":"17","author":"FMFC French","year":"1997","unstructured":"French FMFC (1997) A candidate gene for familial Mediterranean fever. Nat Genet 17:25\u201331. https:\/\/doi.org\/10.1038\/ng0997-25","journal-title":"Nat Genet"},{"key":"9042_CR63","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.cyto.2014.06.012","volume":"69","author":"JN Ibrahim","year":"2014","unstructured":"Ibrahim JN, Jounblat R, Delwail A, Abou-Ghoch J, Salem N, Chouery E et al (2014) Ex vivo PBMC cytokine profile in familial Mediterranean fever patients: Involvement of IL-1beta, IL-1alpha and Th17-associated cytokines and decrease of Th1 and Th2 cytokines. Cytokine 69:248\u2013254. https:\/\/doi.org\/10.1016\/j.cyto.2014.06.012","journal-title":"Cytokine"},{"key":"9042_CR64","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/j.clinbiochem.2008.03.017","volume":"41","author":"GP Manukyan","year":"2008","unstructured":"Manukyan GP, Ghazaryan KA, Ktsoyan ZhA, Tatyan MV, Khachatryan ZA, Hakobyan GS et al (2008) Cytokine profile of Armenian patients with Familial Mediterranean fever. Clin Biochem 41:920\u2013922. https:\/\/doi.org\/10.1016\/j.clinbiochem.2008.03.017","journal-title":"Clin Biochem"},{"key":"9042_CR65","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ajpath.2012.03.044","volume":"181","author":"MS Maddur","year":"2012","unstructured":"Maddur MS, Miossec P, Kaveri SV, Bayry J (2012) Th17 cells: biology, pathogenesis of autoimmune and inflammatory diseases, and therapeutic strategies. Am J Pathol 181:8\u201318. https:\/\/doi.org\/10.1016\/j.ajpath.2012.03.044","journal-title":"Am J Pathol"},{"key":"9042_CR66","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1007\/s00296-006-0301-6","volume":"27","author":"I Simsek","year":"2007","unstructured":"Simsek I, Pay S, Pekel A, Dinc A, Musabak U, Erdem H et al (2007) Serum proinflammatory cytokines directing T helper 1 polarization in patients with familial Mediterranean fever. Rheumatol Int 27:807\u2013811. https:\/\/doi.org\/10.1007\/s00296-006-0301-6","journal-title":"Rheumatol Int"},{"key":"9042_CR67","unstructured":"Aypar E, Ozen S, Okur H, Kutluk T, Besbas N, Bakkaloglu A (2003) Th1 polarization in familial Mediterranean fever. J Rheumatol. 30:2011\u20132013. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/12966607"},{"key":"9042_CR68","doi-asserted-by":"publisher","first-page":"2711","DOI":"10.1093\/rheumatology\/keaa205","volume":"59","author":"JB Kuemmerle-Deschner","year":"2020","unstructured":"Kuemmerle-Deschner JB, Gautam R, George AT, Raza S, Lomax KG, Hur P (2020) A systematic literature review of efficacy, effectiveness and safety of biologic therapies for treatment of familial Mediterranean fever. Rheumatology (Oxford) 59:2711\u20132724. https:\/\/doi.org\/10.1093\/rheumatology\/keaa205","journal-title":"Rheumatology (Oxford)"},{"issue":"79\u201391","key":"9042_CR69","doi-asserted-by":"publisher","first-page":"e16","DOI":"10.1016\/j.cell.2019.11.026","volume":"180","author":"JY Lee","year":"2020","unstructured":"Lee JY, Hall JA, Kroehling L, Wu L, Najar T, Nguyen HH et al (2020) Serum Amyloid A Proteins Induce Pathogenic Th17 Cells and Promote Inflammatory Disease. Cell 180(79\u201391):e16. https:\/\/doi.org\/10.1016\/j.cell.2019.11.026","journal-title":"Cell"},{"key":"9042_CR70","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1093\/mrcr\/rxac031","volume":"7","author":"T Goto","year":"2023","unstructured":"Goto T, Miyazaki Y, Nakayamada S, Shiraishi N, Yoshinaga T, Tanaka Y et al (2023) Down-regulated Th17 cells in a patient with familial Mediterranean fever associated with amyloid A amyloidosis in the treatment of canakinumab. Mod Rheumatol Case Rep 7:237\u2013242. https:\/\/doi.org\/10.1093\/mrcr\/rxac031","journal-title":"Mod Rheumatol Case Rep"},{"key":"9042_CR71","doi-asserted-by":"publisher","first-page":"29","DOI":"10.5152\/EuJRheum.2022.21180","volume":"10","author":"D Yildirim","year":"2023","unstructured":"Yildirim D, Kardas RC, Ozkiziltas B, Vasi I, Kucuk H, Ozturk MA et al (2023) Dual Biologic Therapy in Patients with Familial Mediterranean Fever and Spondyloarthritis: Case-Based Review. Eur J Rheumatol 10:29\u201333. https:\/\/doi.org\/10.5152\/EuJRheum.2022.21180","journal-title":"Eur J Rheumatol"},{"key":"9042_CR72","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1111\/j.1365-2567.2011.03522.x","volume":"135","author":"C Tang","year":"2012","unstructured":"Tang C, Chen S, Qian H, Huang W (2012) Interleukin-23: as a drug target for autoimmune inflammatory diseases. Immunology 135:112\u2013124. https:\/\/doi.org\/10.1111\/j.1365-2567.2011.03522.x","journal-title":"Immunology"},{"key":"9042_CR73","doi-asserted-by":"publisher","first-page":"21351","DOI":"10.1038\/s41598-024-72736-x","volume":"14","author":"M Hizal","year":"2024","unstructured":"Hizal M, Tufan A, Mercan R, Pasaoglu OT, Pasaoglu H, Haznedaroglu S et al (2024) Interleukin-21 and Interleukin-23 levels in familial Mediterranean Fever before and after treatment: the role of cytokines in disease pathogenesis. Sci Rep 14:21351. https:\/\/doi.org\/10.1038\/s41598-024-72736-x","journal-title":"Sci Rep"},{"key":"9042_CR74","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s00296-019-04412-7","volume":"40","author":"N Atas","year":"2020","unstructured":"Atas N, Armagan B, Bodakci E, Satis H, Sari A, Bilge NSY et al (2020) Familial Mediterranean fever is associated with a wide spectrum of inflammatory disorders: results from a large cohort study. Rheumatol Int 40:41\u201348. https:\/\/doi.org\/10.1007\/s00296-019-04412-7","journal-title":"Rheumatol Int"},{"key":"9042_CR75","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/j.ophtha.2022.03.014","volume":"129","author":"Z Zhong","year":"2022","unstructured":"Zhong Z, Ding J, Su G, Liao W, Gao Y, Zhu Y et al (2022) Genetic and Clinical Features of Blau Syndrome among Chinese Patients with Uveitis. Ophthalmology 129:821\u2013828. https:\/\/doi.org\/10.1016\/j.ophtha.2022.03.014","journal-title":"Ophthalmology"},{"issue":"339\u2013349","key":"9042_CR76","doi-asserted-by":"publisher","first-page":"e311","DOI":"10.1016\/j.jaci.2017.04.013","volume":"141","author":"S Takada","year":"2018","unstructured":"Takada S, Kambe N, Kawasaki Y, Niwa A, Honda-Ozaki F, Kobayashi K et al (2018) Pluripotent stem cell models of Blau syndrome reveal an IFN-gamma-dependent inflammatory response in macrophages. J Allergy Clin Immunol 141(339\u2013349):e311. https:\/\/doi.org\/10.1016\/j.jaci.2017.04.013","journal-title":"J Allergy Clin Immunol"},{"key":"9042_CR77","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1182\/blood-2004-07-2972","volume":"105","author":"N Kanazawa","year":"2005","unstructured":"Kanazawa N, Okafuji I, Kambe N, Nishikomori R, Nakata-Hizume M, Nagai S et al (2005) Early-onset sarcoidosis and CARD15 mutations with constitutive nuclear factor-kappaB activation: common genetic etiology with Blau syndrome. Blood 105:1195\u20131197. https:\/\/doi.org\/10.1182\/blood-2004-07-2972","journal-title":"Blood"},{"issue":"176\u2013188","key":"9042_CR78","doi-asserted-by":"publisher","first-page":"e177","DOI":"10.1016\/j.jaci.2021.05.030","volume":"149","author":"Y Kitagawa","year":"2022","unstructured":"Kitagawa Y, Kawasaki Y, Yamasaki Y, Kambe N, Takei S, Saito MK (2022) Anti-TNF treatment corrects IFN-gamma-dependent proinflammatory signatures in Blau syndrome patient-derived macrophages. J Allergy Clin Immunol 149(176\u2013188):e177. https:\/\/doi.org\/10.1016\/j.jaci.2021.05.030","journal-title":"J Allergy Clin Immunol"},{"key":"9042_CR79","doi-asserted-by":"publisher","unstructured":"Yao Q, Shen M, McDonald C, Lacbawan F, Moran R, Shen B (2015) NOD2-associated autoinflammatory disease: a large cohort study. Rheumatology (Oxford).54:1904\u20131912. https:\/\/doi.org\/10.1093\/rheumatology\/kev207","DOI":"10.1093\/rheumatology\/kev207"},{"key":"9042_CR80","doi-asserted-by":"publisher","unstructured":"Yao Q, Shen B (2017) A Systematic Analysis of Treatment and Outcomes of NOD2-Associated Autoinflammatory Disease. Am J Med. 130:365 e313\u2013365 e318. https:\/\/doi.org\/10.1016\/j.amjmed.2016.09.028","DOI":"10.1016\/j.amjmed.2016.09.028"},{"key":"9042_CR81","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1080\/08916934.2018.1442442","volume":"51","author":"C McDonald","year":"2018","unstructured":"McDonald C, Shen M, Johnson EE, Kabi A, Yao Q (2018) Alterations in nucleotide-binding oligomerization domain-2 expression, pathway activation, and cytokine production in Yao syndrome. Autoimmunity 51:53\u201361. https:\/\/doi.org\/10.1080\/08916934.2018.1442442","journal-title":"Autoimmunity"},{"key":"9042_CR82","doi-asserted-by":"publisher","first-page":"471","DOI":"10.3109\/09273948.2012.726391","volume":"20","author":"SC Paparizos","year":"2012","unstructured":"Paparizos SC, Goldstein DA, Bouhenni RA, Steiner S, Dunmire JJ, Edward DP (2012) Immunohistochemical evidence of specific iris involvement in Blau syndrome. Ocul Immunol Inflamm 20:471\u2013474. https:\/\/doi.org\/10.3109\/09273948.2012.726391","journal-title":"Ocul Immunol Inflamm"},{"key":"9042_CR83","doi-asserted-by":"publisher","first-page":"4414","DOI":"10.4049\/jimmunol.0903332","volume":"184","author":"Y Okamoto Yoshida","year":"2010","unstructured":"Okamoto Yoshida Y, Umemura M, Yahagi A, O\u2019Brien RL, Ikuta K, Kishihara K et al (2010) Essential role of IL-17A in the formation of a mycobacterial infection-induced granuloma in the lung. J Immunol 184:4414\u20134422. https:\/\/doi.org\/10.4049\/jimmunol.0903332","journal-title":"J Immunol"},{"key":"9042_CR84","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.det.2016.07.005","volume":"35","author":"KW Shwin","year":"2017","unstructured":"Shwin KW, Lee CR, Goldbach-Mansky R (2017) Dermatologic Manifestations of Monogenic Autoinflammatory Diseases. Dermatol Clin 35:21\u201338. https:\/\/doi.org\/10.1016\/j.det.2016.07.005","journal-title":"Dermatol Clin"},{"issue":"66\u201379","key":"9042_CR85","doi-asserted-by":"publisher","first-page":"e65","DOI":"10.1016\/j.immuni.2018.05.012","volume":"49","author":"M Wang","year":"2018","unstructured":"Wang M, Zhang S, Zheng G, Huang J, Songyang Z, Zhao X et al (2018) Gain-of-Function Mutation of Card14 Leads to Spontaneous Psoriasis-like Skin Inflammation through Enhanced Keratinocyte Response to IL-17A. Immunity 49(66\u201379):e65. https:\/\/doi.org\/10.1016\/j.immuni.2018.05.012","journal-title":"Immunity"},{"key":"9042_CR86","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1016\/j.jid.2018.03.1525","volume":"138","author":"M Mellett","year":"2018","unstructured":"Mellett M, Meier B, Mohanan D, Schairer R, Cheng P, Satoh TK et al (2018) CARD14 Gain-of-Function Mutation Alone Is Sufficient to Drive IL-23\/IL-17-Mediated Psoriasiform Skin Inflammation In Vivo. J Invest Dermatol 138:2010\u20132023. https:\/\/doi.org\/10.1016\/j.jid.2018.03.1525","journal-title":"J Invest Dermatol"},{"key":"9042_CR87","doi-asserted-by":"publisher","first-page":"71","DOI":"10.4049\/jimmunol.1700995","volume":"200","author":"M Tanaka","year":"2018","unstructured":"Tanaka M, Kobiyama K, Honda T, Uchio-Yamada K, Natsume-Kitatani Y, Mizuguchi K et al (2018) Essential Role of CARD14 in Murine Experimental Psoriasis. J Immunol 200:71\u201381. https:\/\/doi.org\/10.4049\/jimmunol.1700995","journal-title":"J Immunol"},{"key":"9042_CR88","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s13555-015-0092-3","volume":"6","author":"M Campa","year":"2016","unstructured":"Campa M, Mansouri B, Warren R, Menter A (2016) A Review of Biologic Therapies Targeting IL-23 and IL-17 for Use in Moderate-to-Severe Plaque Psoriasis. Dermatol Ther (Heidelb) 6:1\u201312. https:\/\/doi.org\/10.1007\/s13555-015-0092-3","journal-title":"Dermatol Ther (Heidelb)"},{"key":"9042_CR89","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1007\/s11914-017-0405-9","volume":"15","author":"SR Hofmann","year":"2017","unstructured":"Hofmann SR, Kapplusch F, Girschick HJ, Morbach H, Pablik J, Ferguson PJ et al (2017) Chronic Recurrent Multifocal Osteomyelitis (CRMO): Presentation, Pathogenesis, and Treatment. Curr Osteoporos Rep 15:542\u2013554. https:\/\/doi.org\/10.1007\/s11914-017-0405-9","journal-title":"Curr Osteoporos Rep"},{"key":"9042_CR90","doi-asserted-by":"publisher","first-page":"256","DOI":"10.3389\/fped.2017.00256","volume":"5","author":"SR Hofmann","year":"2017","unstructured":"Hofmann SR, Bottger F, Range U, Luck C, Morbach H, Girschick HJ et al (2017) Serum Interleukin-6 and CCL11\/Eotaxin May Be Suitable Biomarkers for the Diagnosis of Chronic Nonbacterial Osteomyelitis. Front Pediatr 5:256. https:\/\/doi.org\/10.3389\/fped.2017.00256","journal-title":"Front Pediatr"},{"key":"9042_CR91","doi-asserted-by":"publisher","first-page":"155521","DOI":"10.1016\/j.cyto.2021.155521","volume":"143","author":"MM Kostik","year":"2021","unstructured":"Kostik MM, Makhova MA, Maletin AS, Magomedova SM, Sorokina LS, Tsukasaki M et al (2021) Cytokine profile in patients with chronic non-bacterial osteomyelitis, juvenile idiopathic arthritis, and insulin-dependent diabetes mellitus. Cytokine 143:155521. https:\/\/doi.org\/10.1016\/j.cyto.2021.155521","journal-title":"Cytokine"},{"key":"9042_CR92","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1002\/eji.201141871","volume":"42","author":"K Zwerina","year":"2012","unstructured":"Zwerina K, Koenders M, Hueber A, Marijnissen RJ, Baum W, Heiland GR et al (2012) Anti IL-17A therapy inhibits bone loss in TNF-alpha-mediated murine arthritis by modulation of the T-cell balance. Eur J Immunol 42:413\u2013423. https:\/\/doi.org\/10.1002\/eji.201141871","journal-title":"Eur J Immunol"},{"key":"9042_CR93","doi-asserted-by":"publisher","first-page":"109344","DOI":"10.1016\/j.clim.2023.109344","volume":"251","author":"CM Hedrich","year":"2023","unstructured":"Hedrich CM, Beresford MW, Dedeoglu F, Hahn G, Hofmann SR, Jansson AF et al (2023) Gathering expert consensus to inform a proposed trial in chronic nonbacterial osteomyelitis (CNO). Clin Immunol 251:109344. https:\/\/doi.org\/10.1016\/j.clim.2023.109344","journal-title":"Clin Immunol"},{"key":"9042_CR94","doi-asserted-by":"publisher","unstructured":"Li SWS, Roberts E, Hedrich C (2023) Treatment and monitoring of SAPHO syndrome: a systematic review. RMD Open.9. https:\/\/doi.org\/10.1136\/rmdopen-2023-003688","DOI":"10.1136\/rmdopen-2023-003688"},{"key":"9042_CR95","doi-asserted-by":"publisher","first-page":"389","DOI":"10.3109\/08916934.2014.906582","volume":"47","author":"D Firinu","year":"2014","unstructured":"Firinu D, Barca MP, Lorrai MM, Perra S, Cabras S, Muggianu E et al (2014) TH17 cells are increased in the peripheral blood of patients with SAPHO syndrome. Autoimmunity 47:389\u2013394. https:\/\/doi.org\/10.3109\/08916934.2014.906582","journal-title":"Autoimmunity"},{"key":"9042_CR96","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.jbspin.2017.05.016","volume":"84","author":"D Wendling","year":"2017","unstructured":"Wendling D, Aubin F, Verhoeven F, Prati C (2017) IL-23\/Th17 targeted therapies in SAPHO syndrome. A case series Joint Bone Spine 84:733\u2013735. https:\/\/doi.org\/10.1016\/j.jbspin.2017.05.016","journal-title":"A case series Joint Bone Spine"},{"key":"9042_CR97","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1684\/ejd.2016.2854","volume":"26","author":"H Cornillier","year":"2016","unstructured":"Cornillier H, Kervarrec T, Tabareau-Delalande F, Mammou S, Jonville Bera AP, Machet L (2016) Interstitial granulomatous dermatitis occurring in a patient with SAPHO syndrome one month after starting leflunomide, and subsequently disappearing with ustekinumab. Eur J Dermatol 26:614\u2013615. https:\/\/doi.org\/10.1684\/ejd.2016.2854","journal-title":"Eur J Dermatol"},{"key":"9042_CR98","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s10067-019-04675-2","volume":"39","author":"ASB Figueiredo","year":"2020","unstructured":"Figueiredo ASB, Oliveira AL, Caetano A, Moraes-Fontes MF (2020) SAPHO: has the time come for tailored therapy? Clin Rheumatol 39:177\u2013187. https:\/\/doi.org\/10.1007\/s10067-019-04675-2","journal-title":"Clin Rheumatol"},{"key":"9042_CR99","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1111\/bjd.16071","volume":"179","author":"S Adamo","year":"2018","unstructured":"Adamo S, Nilsson J, Krebs A, Steiner U, Cozzio A, French LE et al (2018) Successful treatment of SAPHO syndrome with apremilast. Br J Dermatol 179:959\u2013962. https:\/\/doi.org\/10.1111\/bjd.16071","journal-title":"Br J Dermatol"},{"key":"9042_CR100","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s11926-016-0583-y","volume":"18","author":"D Firinu","year":"2016","unstructured":"Firinu D, Garcia-Larsen V, Manconi PE, Del Giacco SR (2016) SAPHO Syndrome: Current Developments and Approaches to Clinical Treatment. Curr Rheumatol Rep 18:35. https:\/\/doi.org\/10.1007\/s11926-016-0583-y","journal-title":"Curr Rheumatol Rep"},{"key":"9042_CR101","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1136\/annrheumdis-2021-221035","volume":"80","author":"V Navarro-Compan","year":"2021","unstructured":"Navarro-Compan V, Sepriano A, El-Zorkany B, van der Heijde D (2021) Axial spondyloarthritis. Ann Rheum Dis 80:1511\u20131521. https:\/\/doi.org\/10.1136\/annrheumdis-2021-221035","journal-title":"Ann Rheum Dis"},{"key":"9042_CR102","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1111\/ddg.15055","volume":"21","author":"H Bonnekoh","year":"2023","unstructured":"Bonnekoh H, Erpenbeck L (2023) Neutrophilic dermatoses - Pathomechanistic concepts and therapeutic developments. J Dtsch Dermatol Ges 21:374\u2013380. https:\/\/doi.org\/10.1111\/ddg.15055","journal-title":"J Dtsch Dermatol Ges"},{"key":"9042_CR103","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1093\/hmg\/11.8.961","volume":"11","author":"CA Wise","year":"2002","unstructured":"Wise CA, Gillum JD, Seidman CE, Lindor NM, Veile R, Bashiardes S et al (2002) Mutations in CD2BP1 disrupt binding to PTP PEST and are responsible for PAPA syndrome, an autoinflammatory disorder. Hum Mol Genet 11:961\u2013969. https:\/\/doi.org\/10.1093\/hmg\/11.8.961","journal-title":"Hum Mol Genet"},{"key":"9042_CR104","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.jaad.2010.12.025","volume":"66","author":"M Braun-Falco","year":"2012","unstructured":"Braun-Falco M, Kovnerystyy O, Lohse P, Ruzicka T (2012) Pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH)\u2013a new autoinflammatory syndrome distinct from PAPA syndrome. J Am Acad Dermatol 66:409\u2013415. https:\/\/doi.org\/10.1016\/j.jaad.2010.12.025","journal-title":"J Am Acad Dermatol"},{"key":"9042_CR105","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1001\/jamadermatol.2013.2907","volume":"149","author":"AV Marzano","year":"2013","unstructured":"Marzano AV, Trevisan V, Gattorno M, Ceccherini I, De Simone C, Crosti C (2013) Pyogenic arthritis, pyoderma gangrenosum, acne, and hidradenitis suppurativa (PAPASH): a new autoinflammatory syndrome associated with a novel mutation of the PSTPIP1 gene. JAMA Dermatol 149:762\u2013764. https:\/\/doi.org\/10.1001\/jamadermatol.2013.2907","journal-title":"JAMA Dermatol"},{"key":"9042_CR106","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1159\/000509873","volume":"237","author":"G Nikolakis","year":"2021","unstructured":"Nikolakis G, Kaleta KP, Vaiopoulos AG, Wolter K, Baroud S, Wojas-Pelc A et al (2021) Phenotypes and Pathophysiology of Syndromic Hidradenitis Suppurativa: Different Faces of the Same Disease? A Systematic Review. Dermatology 237:673\u2013697. https:\/\/doi.org\/10.1159\/000509873","journal-title":"Dermatology"},{"key":"9042_CR107","doi-asserted-by":"publisher","first-page":"1339337","DOI":"10.3389\/fimmu.2023.1339337","volume":"14","author":"JL Sanz-Cabanillas","year":"2023","unstructured":"Sanz-Cabanillas JL, Gomez-Garcia F, Gomez-Arias PJ, Montilla-Lopez A, Gay-Mimbrera J, Ruano J et al (2023) Efficacy and safety of anakinra and canakinumab in PSTPIP1-associated inflammatory diseases: a comprehensive scoping review. Front Immunol 14:1339337. https:\/\/doi.org\/10.3389\/fimmu.2023.1339337","journal-title":"Front Immunol"},{"key":"9042_CR108","doi-asserted-by":"publisher","first-page":"2389","DOI":"10.1016\/j.jid.2017.05.033","volume":"137","author":"B Moran","year":"2017","unstructured":"Moran B, Sweeney CM, Hughes R, Malara A, Kirthi S, Tobin AM et al (2017) Hidradenitis Suppurativa Is Characterized by Dysregulation of the Th17: Treg Cell Axis, Which Is Corrected by Anti-TNF Therapy. J Invest Dermatol 137:2389\u20132395. https:\/\/doi.org\/10.1016\/j.jid.2017.05.033","journal-title":"J Invest Dermatol"},{"key":"9042_CR109","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1111\/bjd.13670","volume":"173","author":"M Caproni","year":"2015","unstructured":"Caproni M, Antiga E, Volpi W, Verdelli A, Venegoni L, Quaglino P et al (2015) The Treg\/Th17 cell ratio is reduced in the skin lesions of patients with pyoderma gangrenosum. Br J Dermatol 173:275\u2013278. https:\/\/doi.org\/10.1111\/bjd.13670","journal-title":"Br J Dermatol"},{"key":"9042_CR110","doi-asserted-by":"publisher","first-page":"e187","DOI":"10.1097\/MD.0000000000000187","volume":"93","author":"AV Marzano","year":"2014","unstructured":"Marzano AV, Ceccherini I, Gattorno M, Fanoni D, Caroli F, Rusmini M et al (2014) Association of pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH) shares genetic and cytokine profiles with other autoinflammatory diseases. Medicine (Baltimore) 93:e187. https:\/\/doi.org\/10.1097\/MD.0000000000000187","journal-title":"Medicine (Baltimore)"},{"key":"9042_CR111","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1111\/cei.12394","volume":"178","author":"AV Marzano","year":"2014","unstructured":"Marzano AV, Fanoni D, Antiga E, Quaglino P, Caproni M, Crosti C et al (2014) Expression of cytokines, chemokines and other effector molecules in two prototypic autoinflammatory skin diseases, pyoderma gangrenosum and Sweet\u2019s syndrome. Clin Exp Immunol 178:48\u201356. https:\/\/doi.org\/10.1111\/cei.12394","journal-title":"Clin Exp Immunol"},{"key":"9042_CR112","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1111\/jdv.12631","volume":"30","author":"N Garzorz","year":"2016","unstructured":"Garzorz N, Papanagiotou V, Atenhan A, Andres C, Eyerich S, Eyerich K et al (2016) Pyoderma gangrenosum, acne, psoriasis, arthritis and suppurative hidradenitis (PAPASH)-syndrome: a new entity within the spectrum of autoinflammatory syndromes? J Eur Acad Dermatol Venereol 30:141\u2013143. https:\/\/doi.org\/10.1111\/jdv.12631","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"9042_CR113","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s00403-024-03509-9","volume":"317","author":"MH Ali","year":"2024","unstructured":"Ali MH, Mohiyuddin Z, Tareen MK, Safdar MF, Talha M (2024) Safety and efficacy of IL-17 inhibitors in hidradenitis suppurativa: an updated systematic review and meta-analysis including the BE-HEARD trials. Arch Dermatol Res 317:12. https:\/\/doi.org\/10.1007\/s00403-024-03509-9","journal-title":"Arch Dermatol Res"},{"key":"9042_CR114","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s40259-024-00687-w","volume":"39","author":"G Pinto Salgueiro","year":"2025","unstructured":"Pinto Salgueiro G, Yilmaz O, Nogueira M, Torres T (2025) Interleukin-17 Inhibitors in the Treatment of Hidradenitis Suppurativa. BioDrugs 39:53\u201374. https:\/\/doi.org\/10.1007\/s40259-024-00687-w","journal-title":"BioDrugs"},{"key":"9042_CR115","doi-asserted-by":"publisher","unstructured":"Nikolakis G, Kreibich K, Vaiopoulos A, Kaleta K, Talas J, Becker M, et al. (2021) Case Report: PsAPSASH syndrome: an alternative phenotype of syndromic hidradenitis suppurativa treated with the IL-17A inhibitor secukinumab. F1000Research. 10:381. https:\/\/doi.org\/10.12688\/f1000research.52100.2","DOI":"10.12688\/f1000research.52100.2"},{"key":"9042_CR116","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1056\/NEJMoa1013068","volume":"365","author":"S Marrakchi","year":"2011","unstructured":"Marrakchi S, Guigue P, Renshaw BR, Puel A, Pei XY, Fraitag S et al (2011) Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. N Engl J Med 365:620\u2013628. https:\/\/doi.org\/10.1056\/NEJMoa1013068","journal-title":"N Engl J Med"},{"key":"9042_CR117","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.1038\/jid.2011.234","volume":"131","author":"Y Carrier","year":"2011","unstructured":"Carrier Y, Ma HL, Ramon HE, Napierata L, Small C, O\u2019Toole M et al (2011) Inter-regulation of Th17 cytokines and the IL-36 cytokines in vitro and in vivo: implications in psoriasis pathogenesis. J Invest Dermatol 131:2428\u20132437. https:\/\/doi.org\/10.1038\/jid.2011.234","journal-title":"J Invest Dermatol"},{"key":"9042_CR118","doi-asserted-by":"publisher","first-page":"15631","DOI":"10.1038\/s41598-017-15892-7","volume":"7","author":"CM Pfaff","year":"2017","unstructured":"Pfaff CM, Marquardt Y, Fietkau K, Baron JM, Luscher B (2017) The psoriasis-associated IL-17A induces and cooperates with IL-36 cytokines to control keratinocyte differentiation and function. Sci Rep 7:15631. https:\/\/doi.org\/10.1038\/s41598-017-15892-7","journal-title":"Sci Rep"},{"key":"9042_CR119","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1093\/rheumatology\/kex510","volume":"57","author":"K Kostner","year":"2018","unstructured":"Kostner K, Prelog M, Almanzar G, Fesq H, Haas JP, Hugle B (2018) Successful use of secukinumab in a 4-year-old patient with deficiency of interleukin-36 antagonist. Rheumatology (Oxford) 57:936\u2013938. https:\/\/doi.org\/10.1093\/rheumatology\/kex510","journal-title":"Rheumatology (Oxford)"},{"key":"9042_CR120","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1111\/pde.14737","volume":"38","author":"G Jing","year":"2021","unstructured":"Jing G, Bin W, Ying ZZ (2021) Rapid response to secukinumab in a 5-year-old with deficiency of the interleukin-36 receptor antagonist (DITRA) with severe scalp and nail involvement. Pediatr Dermatol 38:1258\u20131263. https:\/\/doi.org\/10.1111\/pde.14737","journal-title":"Pediatr Dermatol"},{"key":"9042_CR121","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1001\/jamadermatol.2016.3490","volume":"153","author":"KM Cordoro","year":"2017","unstructured":"Cordoro KM, Ucmak D, Hitraya-Low M, Rosenblum MD, Liao W (2017) Response to Interleukin (IL)-17 Inhibition in an Adolescent With Severe Manifestations of IL-36 Receptor Antagonist Deficiency (DITRA). JAMA Dermatol 153:106\u2013108. https:\/\/doi.org\/10.1001\/jamadermatol.2016.3490","journal-title":"JAMA Dermatol"},{"key":"9042_CR122","doi-asserted-by":"publisher","first-page":"3461","DOI":"10.1002\/art.23957","volume":"58","author":"MI Koenders","year":"2008","unstructured":"Koenders MI, Devesa I, Marijnissen RJ, Abdollahi-Roodsaz S, Boots AM, Walgreen B et al (2008) Interleukin-1 drives pathogenic Th17 cells during spontaneous arthritis in interleukin-1 receptor antagonist-deficient mice. Arthritis Rheum 58:3461\u20133470. https:\/\/doi.org\/10.1002\/art.23957","journal-title":"Arthritis Rheum"},{"key":"9042_CR123","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1056\/NEJMoa0807865","volume":"360","author":"I Aksentijevich","year":"2009","unstructured":"Aksentijevich I, Masters SL, Ferguson PJ, Dancey P, Frenkel J, van Royen-Kerkhoff A et al (2009) An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N Engl J Med 360:2426\u20132437. https:\/\/doi.org\/10.1056\/NEJMoa0807865","journal-title":"N Engl J Med"},{"key":"9042_CR124","doi-asserted-by":"publisher","first-page":"5986","DOI":"10.1073\/pnas.1035999100","volume":"100","author":"S Nakae","year":"2003","unstructured":"Nakae S, Saijo S, Horai R, Sudo K, Mori S, Iwakura Y (2003) IL-17 production from activated T cells is required for the spontaneous development of destructive arthritis in mice deficient in IL-1 receptor antagonist. Proc Natl Acad Sci USA 100:5986\u20135990. https:\/\/doi.org\/10.1073\/pnas.1035999100","journal-title":"Proc Natl Acad Sci USA"},{"key":"9042_CR125","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1111\/bjd.13857","volume":"173","author":"HD de Koning","year":"2015","unstructured":"de Koning HD, van Vlijmen-Willems IM, Rodijk-Olthuis D, van der Meer JW, Zeeuwen PL, Simon A et al (2015) Mast-cell interleukin-1beta, neutrophil interleukin-17 and epidermal antimicrobial proteins in the neutrophilic urticarial dermatosis in Schnitzler\u2019s syndrome. Br J Dermatol 173:448\u2013456. https:\/\/doi.org\/10.1111\/bjd.13857","journal-title":"Br J Dermatol"},{"key":"9042_CR126","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.anai.2017.10.006","volume":"120","author":"RS Villarreal","year":"2018","unstructured":"Villarreal RS, VandenBoom T, Gonzalez-Gonzalez FJ, Carter RG, Peters NT, Peters AT et al (2018) Schnitzler syndrome with IgG gammopathy and elevated IL-1beta and IL-17 in skin biopsy. Ann Allergy Asthma Immunol 120:99\u2013101. https:\/\/doi.org\/10.1016\/j.anai.2017.10.006","journal-title":"Ann Allergy Asthma Immunol"},{"key":"9042_CR127","doi-asserted-by":"publisher","first-page":"1050230","DOI":"10.3389\/fmed.2023.1050230","volume":"10","author":"S Bossart","year":"2023","unstructured":"Bossart S, SeyedJafari SM, Heidemeyer K, Yan K, Feldmeyer L, Borradori L et al (2023) Canakinumab leads to rapid reduction of neutrophilic inflammation and long-lasting response in Schnitzler syndrome. Front Med (Lausanne) 10:1050230. https:\/\/doi.org\/10.3389\/fmed.2023.1050230","journal-title":"Front Med (Lausanne)"},{"key":"9042_CR128","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1111\/cei.13306","volume":"197","author":"OH Negm","year":"2019","unstructured":"Negm OH, Singh S, Abduljabbar W, Hamed MR, Radford P, McDermott EM et al (2019) Patients with tumour necrosis factor (TNF) receptor-associated periodic syndrome (TRAPS) are hypersensitive to Toll-like receptor 9 stimulation. Clin Exp Immunol 197:352\u2013360. https:\/\/doi.org\/10.1111\/cei.13306","journal-title":"Clin Exp Immunol"},{"key":"9042_CR129","doi-asserted-by":"publisher","unstructured":"Timilshina M, You Z, Lacher SM, Acharya S, Jiang L, Kang Y, et al. (2019) Activation of Mevalonate Pathway via LKB1 Is Essential for Stability of T(reg) Cells. Cell reports. 27:2948\u20132961 e2947. https:\/\/doi.org\/10.1016\/j.celrep.2019.05.020","DOI":"10.1016\/j.celrep.2019.05.020"},{"key":"9042_CR130","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/pr.2013.96","volume":"74","author":"A Marcuzzi","year":"2013","unstructured":"Marcuzzi A, Zanin V, Kleiner G, Monasta L, Crovella S (2013) Mouse model of mevalonate kinase deficiency: comparison of cytokine and chemokine profile with that of human patients. Pediatr Res 74:266\u2013271. https:\/\/doi.org\/10.1038\/pr.2013.96","journal-title":"Pediatr Res"},{"key":"9042_CR131","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1136\/annrheumdis-2016-210021","volume":"76","author":"S Grandemange","year":"2017","unstructured":"Grandemange S, Sanchez E, Louis-Plence P, Tran Mau-Them F, Bessis D, Coubes C et al (2017) A new autoinflammatory and autoimmune syndrome associated with NLRP1 mutations: NAIAD (NLRP1-associated autoinflammation with arthritis and dyskeratosis). Ann Rheum Dis 76:1191\u20131198. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210021","journal-title":"Ann Rheum Dis"},{"key":"9042_CR132","doi-asserted-by":"publisher","first-page":"19055","DOI":"10.1073\/pnas.1906184116","volume":"116","author":"SB Drutman","year":"2019","unstructured":"Drutman SB, Haerynck F, Zhong FL, Hum D, Hernandez NJ, Belkaya S et al (2019) Homozygous NLRP1 gain-of-function mutation in siblings with a syndromic form of recurrent respiratory papillomatosis. Proc Natl Acad Sci USA 116:19055\u201319063. https:\/\/doi.org\/10.1073\/pnas.1906184116","journal-title":"Proc Natl Acad Sci USA"},{"issue":"187\u2013202","key":"9042_CR133","doi-asserted-by":"publisher","first-page":"e117","DOI":"10.1016\/j.cell.2016.09.001","volume":"167","author":"FL Zhong","year":"2016","unstructured":"Zhong FL, Mamai O, Sborgi L, Boussofara L, Hopkins R, Robinson K et al (2016) Germline NLRP1 Mutations Cause Skin Inflammatory and Cancer Susceptibility Syndromes via Inflammasome Activation. Cell 167(187\u2013202):e117. https:\/\/doi.org\/10.1016\/j.cell.2016.09.001","journal-title":"Cell"},{"key":"9042_CR134","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1056\/NEJMoa061592","volume":"356","author":"Y Jin","year":"2007","unstructured":"Jin Y, Mailloux CM, Gowan K, Riccardi SL, LaBerge G, Bennett DC et al (2007) NALP1 in vitiligo-associated multiple autoimmune disease. N Engl J Med 356:1216\u20131225. https:\/\/doi.org\/10.1056\/NEJMoa061592","journal-title":"N Engl J Med"},{"key":"9042_CR135","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1093\/bjd\/ljac039","volume":"188","author":"M Li","year":"2023","unstructured":"Li M, Lay K, Zimmer A, Technau-Hafsi K, Wong J, Reimer-Taschenbrecker A et al (2023) A homozygous p.Leu813Pro gain-of-function NLRP1 variant causes phenotypes of different severity in two siblings. Br J Dermatol 188:259\u2013267. https:\/\/doi.org\/10.1093\/bjd\/ljac039","journal-title":"Br J Dermatol"},{"key":"9042_CR136","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.1007\/s10620-019-05525-6","volume":"64","author":"N Jacob","year":"2019","unstructured":"Jacob N, Dasharathy SS, Bui V, Benhammou JN, Grody WW, Singh RR et al (2019) Generalized Cytokine Increase in the Setting of a Multisystem Clinical Disorder and Carcinoid Syndrome Associated with a Novel NLRP12 Variant. Dig Dis Sci 64:2140\u20132146. https:\/\/doi.org\/10.1007\/s10620-019-05525-6","journal-title":"Dig Dis Sci"},{"key":"9042_CR137","doi-asserted-by":"publisher","unstructured":"Malvaso D, Calabrese L, Chiricozzi A, Antonelli F, Coscarella G, Rubegni P, et al. (2023) IL-17 Inhibition: A Valid Therapeutic Strategy in the Management of Hidradenitis Suppurativa. Pharmaceutics. 15. https:\/\/doi.org\/10.3390\/pharmaceutics15102450","DOI":"10.3390\/pharmaceutics15102450"},{"key":"9042_CR138","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1093\/mrcr\/rxab008","volume":"6","author":"A Unal Enginar","year":"2022","unstructured":"Unal Enginar A, Gundogdu M (2022) Successful treatment of hidradenitis suppurativa with secukinumab in a patient with ankylosing spondylitis and Familial Mediterranean Fever. Mod Rheumatol Case Rep 6:19\u201321. https:\/\/doi.org\/10.1093\/mrcr\/rxab008","journal-title":"Mod Rheumatol Case Rep"},{"key":"9042_CR139","doi-asserted-by":"publisher","first-page":"953","DOI":"10.3899\/jrheum.201260","volume":"48","author":"L Wang","year":"2021","unstructured":"Wang L, Sun B, Li C (2021) Clinical and Radiological Remission of Osteoarticular and Cutaneous Lesions in SAPHO Patients Treated With Secukinumab: A Case Series. J Rheumatol 48:953\u2013955. https:\/\/doi.org\/10.3899\/jrheum.201260","journal-title":"J Rheumatol"},{"key":"9042_CR140","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1093\/rheumatology\/keaa352","volume":"60","author":"B Sun","year":"2021","unstructured":"Sun B, Cao Y, Wang L, Wang M, Li C (2021) Successful treatment of refractory mandibular lesions in SAPHO syndrome with secukinumab. Rheumatology (Oxford) 60:473\u2013474. https:\/\/doi.org\/10.1093\/rheumatology\/keaa352","journal-title":"Rheumatology (Oxford)"},{"key":"9042_CR141","doi-asserted-by":"publisher","first-page":"e30065","DOI":"10.1097\/MD.0000000000030065","volume":"101","author":"Q Ji","year":"2022","unstructured":"Ji Q, Wang Q, Pan W, Hou Y, Wang X, Bian L et al (2022) Exceptional response of skin symptoms to secukinumab treatment in a patient with SAPHO syndrome: Case report and literature review. Medicine (Baltimore) 101:e30065. https:\/\/doi.org\/10.1097\/MD.0000000000030065","journal-title":"Medicine (Baltimore)"},{"key":"9042_CR142","doi-asserted-by":"publisher","first-page":"547","DOI":"10.2147\/CCID.S454057","volume":"17","author":"D Fan","year":"2024","unstructured":"Fan D, Li F, Liu Z, Tang Z, Lv S (2024) Successful Treatment of Refractory Synovitis, Acne, Pustulosis, Hyperostosis, and Osteitis (SAPHO) Syndrome and Paradoxical Psoriasis with Secukinumab: A Case Report. Clin Cosmet Investig Dermatol 17:547\u2013552. https:\/\/doi.org\/10.2147\/CCID.S454057","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"9042_CR143","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s12328-023-01893-9","volume":"17","author":"L Grumme","year":"2024","unstructured":"Grumme L, Dombret S, Knosel T, Skapenko A, Schulze-Koops H (2024) Colitis induced by IL-17A-inhibitors. Clin J Gastroenterol 17:263\u2013270. https:\/\/doi.org\/10.1007\/s12328-023-01893-9","journal-title":"Clin J Gastroenterol"},{"key":"9042_CR144","doi-asserted-by":"publisher","first-page":"9076852","DOI":"10.1155\/2024\/9076852","volume":"2024","author":"M Ferraioli","year":"2024","unstructured":"Ferraioli M, Fiannacca L, Greco E, Cela E, Fatica M, Bergamini A et al (2024) Risankizumab Efficacy in Synovitis, Acne, Pustulosis, Hyperostosis, and Osteitis (SAPHO) Remission: A Case Report on Rheumatologic and Dermatologic Disease Manifestations with Literature Review. Case Reports Immunol 2024:9076852. https:\/\/doi.org\/10.1155\/2024\/9076852","journal-title":"Case Reports Immunol"},{"key":"9042_CR145","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1136\/annrheumdis-2017-eular.4360","volume":"76","author":"G Assmann","year":"2017","unstructured":"Assmann G, Tajali A, Bamberger S, Pfreundschuh M, Schormann C, Neumann F (2017) AB0039 Reduction of TH17+ lymphocytes in part of sapho patients on treatment with secukinumab. Ann Rheum Dis 76:1060. https:\/\/doi.org\/10.1136\/annrheumdis-2017-eular.4360","journal-title":"Ann Rheum Dis"},{"key":"9042_CR146","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1111\/1346-8138.14636","volume":"45","author":"PH Ho","year":"2018","unstructured":"Ho PH, Tsai TF (2018) Successful treatment of refractory juvenile generalized pustular psoriasis with secukinumab monotherapy: A case report and review of published work. J Dermatol 45:1353\u20131356. https:\/\/doi.org\/10.1111\/1346-8138.14636","journal-title":"J Dermatol"},{"key":"9042_CR147","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1001\/jamadermatol.2016.5705","volume":"153","author":"V Molho-Pessach","year":"2017","unstructured":"Molho-Pessach V, Alyan R, Gordon D, Jaradat H, Zlotogorski A (2017) Secukinumab for the Treatment of Deficiency of Interleukin 36 Receptor Antagonist in an Adolescent. JAMA Dermatol 153:473\u2013475. https:\/\/doi.org\/10.1001\/jamadermatol.2016.5705","journal-title":"JAMA Dermatol"},{"key":"9042_CR148","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1007\/s40265-021-01566-2","volume":"81","author":"P Aarts","year":"2021","unstructured":"Aarts P, Dudink K, Vossen A, van Straalen KR, Ardon CB, Prens EP et al (2021) Clinical Implementation of Biologics and Small Molecules in the Treatment of Hidradenitis Suppurativa. Drugs 81:1397\u20131410. https:\/\/doi.org\/10.1007\/s40265-021-01566-2","journal-title":"Drugs"},{"key":"9042_CR149","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1093\/ced\/llad130","volume":"48","author":"N Kearney","year":"2023","unstructured":"Kearney N, Hughes R, Kirby B (2023) Treatment of hidradenitis suppurativa with brodalumab in biologic treatment failures: experiences from a specialty clinic. Clin Exp Dermatol 48:790\u2013792. https:\/\/doi.org\/10.1093\/ced\/llad130","journal-title":"Clin Exp Dermatol"},{"key":"9042_CR150","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1056\/NEJMoa1512711","volume":"375","author":"KB Gordon","year":"2016","unstructured":"Gordon KB, Blauvelt A, Papp KA, Langley RG, Luger T, Ohtsuki M et al (2016) Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis. N Engl J Med 375:345\u2013356. https:\/\/doi.org\/10.1056\/NEJMoa1512711","journal-title":"N Engl J Med"},{"key":"9042_CR151","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1111\/ced.15087","volume":"47","author":"R Xia","year":"2022","unstructured":"Xia R, Diao Z, Zhang Z, Liu J, Yin Z (2022) Successful treatment of synovitis, acne, pustulosis, hyperostosis and osteitis syndrome with ixekizumab. Clin Exp Dermatol 47:978\u2013980. https:\/\/doi.org\/10.1111\/ced.15087","journal-title":"Clin Exp Dermatol"},{"key":"9042_CR152","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/S0140-6736(21)00184-7","volume":"397","author":"K Ghoreschi","year":"2021","unstructured":"Ghoreschi K, Balato A, Enerback C, Sabat R (2021) Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis. Lancet 397:754\u2013766. https:\/\/doi.org\/10.1016\/S0140-6736(21)00184-7","journal-title":"Lancet"},{"key":"9042_CR153","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1136\/annrheumdis-2017-211805","volume":"77","author":"N Bonekamp","year":"2018","unstructured":"Bonekamp N, Caorsi R, Viglizzo GM, Graaf M, Minoia F, Grossi A et al (2018) High-dose ustekinumab for severe childhood deficiency of interleukin-36 receptor antagonist (DITRA). Ann Rheum Dis 77:1241\u20131243. https:\/\/doi.org\/10.1136\/annrheumdis-2017-211805","journal-title":"Ann Rheum Dis"},{"key":"9042_CR154","doi-asserted-by":"publisher","first-page":"e88","DOI":"10.1136\/annrheumdis-2017-212793","volume":"77","author":"B Cherqaoui Jr","year":"2018","unstructured":"Cherqaoui B Jr, Rossi-Semerano L, Piram M, Kone-Paut I (2018) Standard dose of Ustekinumab for childhood-onset deficiency of interleukin-36 receptor antagonist. Ann Rheum Dis 77:e88. https:\/\/doi.org\/10.1136\/annrheumdis-2017-212793","journal-title":"Ann Rheum Dis"},{"key":"9042_CR155","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.jdcr.2021.05.029","volume":"14","author":"A Flora","year":"2021","unstructured":"Flora A, Holland R, Smith A, Frew JW (2021) Rapid and sustained remission of synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome with IL-23p19 antagonist (risankizumab). JAAD Case Rep 14:33\u201336. https:\/\/doi.org\/10.1016\/j.jdcr.2021.05.029","journal-title":"JAAD Case Rep"},{"key":"9042_CR156","doi-asserted-by":"publisher","first-page":"e14758","DOI":"10.1111\/dth.14758","volume":"34","author":"G Licata","year":"2021","unstructured":"Licata G, Gambardella A, Calabrese G, Alfano R, Argenziano G (2021) SAPHO syndrome successful treated with tildrakizumab. Dermatol Ther 34:e14758. https:\/\/doi.org\/10.1111\/dth.14758","journal-title":"Dermatol Ther"},{"key":"9042_CR157","doi-asserted-by":"publisher","first-page":"865","DOI":"10.3389\/fimmu.2020.00865","volume":"11","author":"A Soriano","year":"2020","unstructured":"Soriano A, Soriano M, Espinosa G, Manna R, Emmi G, Cantarini L et al (2020) Current Therapeutic Options for the Main Monogenic Autoinflammatory Diseases and PFAPA Syndrome: Evidence-Based Approach and Proposal of a Practical Guide. Front Immunol 11:865. https:\/\/doi.org\/10.3389\/fimmu.2020.00865","journal-title":"Front Immunol"},{"key":"9042_CR158","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1111\/joim.13334","volume":"290","author":"N Wu","year":"2021","unstructured":"Wu N, Wu D, Zhao M, Miao J, Yu W, Wang Y et al (2021) Clinical benefits of TNF-alpha inhibitors in Chinese adult patients with NLRP3-associated autoinflammatory disease. J Intern Med 290:878\u2013885. https:\/\/doi.org\/10.1111\/joim.13334","journal-title":"J Intern Med"},{"key":"9042_CR159","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1111\/j.1365-2133.2007.07682.x","volume":"156","author":"HH Lee","year":"2007","unstructured":"Lee HH, Song IH, Friedrich M, Gauliard A, Detert J, Rowert J et al (2007) Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists. Br J Dermatol 156:486\u2013491. https:\/\/doi.org\/10.1111\/j.1365-2133.2007.07682.x","journal-title":"Br J Dermatol"},{"key":"9042_CR160","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1136\/ard-2024-225640","volume":"83","author":"J Hadjadj","year":"2024","unstructured":"Hadjadj J, Nguyen Y, Mouloudj D, Bourguiba R, Heiblig M, Aloui H et al (2024) Efficacy and safety of targeted therapies in VEXAS syndrome: retrospective study from the FRENVEX. Ann Rheum Dis 83:1358\u20131367. https:\/\/doi.org\/10.1136\/ard-2024-225640","journal-title":"Ann Rheum Dis"},{"key":"9042_CR161","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s12969-019-0338-1","volume":"17","author":"T Hospach","year":"2019","unstructured":"Hospach T, Glowatzki F, Blankenburg F, Conzelmann D, Stirnkorb C, Mullerschon CS et al (2019) Scoping review of biological treatment of deficiency of interleukin-36 receptor antagonist (DITRA) in children and adolescents. Pediatr Rheumatol Online J 17:37. https:\/\/doi.org\/10.1186\/s12969-019-0338-1","journal-title":"Pediatr Rheumatol Online J"},{"key":"9042_CR162","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1159\/000533370","volume":"239","author":"A Tsiogka","year":"2023","unstructured":"Tsiogka A, Liakou AI, Agiasofitou E, Gregoriou S, Stratigos A, Rigopoulos D et al (2023) Adalimumab-Induced Paradoxical Psoriasis Treated with Biologics Targeting the IL-17\/IL-23 Axis in Patients with Hidradenitis Suppurativa. Dermatology 239:937\u2013941. https:\/\/doi.org\/10.1159\/000533370","journal-title":"Dermatology"},{"key":"9042_CR163","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1038\/nrd3794","volume":"11","author":"P Miossec","year":"2012","unstructured":"Miossec P, Kolls JK (2012) Targeting IL-17 and TH17 cells in chronic inflammation. Nat Rev Drug Discov 11:763\u2013776. https:\/\/doi.org\/10.1038\/nrd3794","journal-title":"Nat Rev Drug Discov"},{"key":"9042_CR164","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1038\/cmi.2015.105","volume":"13","author":"X Song","year":"2016","unstructured":"Song X, He X, Li X, Qian Y (2016) The roles and functional mechanisms of interleukin-17 family cytokines in mucosal immunity. Cell Mol Immunol 13:418\u2013431. https:\/\/doi.org\/10.1038\/cmi.2015.105","journal-title":"Cell Mol Immunol"},{"key":"9042_CR165","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1080\/00365521.2019.1597159","volume":"54","author":"DG Ribaldone","year":"2019","unstructured":"Ribaldone DG, Pellicano R, Vernero M, Caviglia GP, Saracco GM, Morino M et al (2019) Dual biological therapy with anti-TNF, vedolizumab or ustekinumab in inflammatory bowel disease: a systematic review with pool analysis. Scand J Gastroenterol 54:407\u2013413. https:\/\/doi.org\/10.1080\/00365521.2019.1597159","journal-title":"Scand J Gastroenterol"},{"key":"9042_CR166","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1136\/gutjnl-2012-302311","volume":"62","author":"ML Hoivik","year":"2013","unstructured":"Hoivik ML, Moum B, Solberg IC, Henriksen M, Cvancarova M, Bernklev T et al (2013) Work disability in inflammatory bowel disease patients 10 years after disease onset: results from the IBSEN Study. Gut 62:368\u2013375. https:\/\/doi.org\/10.1136\/gutjnl-2012-302311","journal-title":"Gut"},{"key":"9042_CR167","doi-asserted-by":"publisher","first-page":"2448","DOI":"10.3389\/fimmu.2019.02448","volume":"10","author":"I Figueras-Nart","year":"2019","unstructured":"Figueras-Nart I, Mascaro JM Jr, Solanich X, Hernandez-Rodriguez J (2019) Dermatologic and Dermatopathologic Features of Monogenic Autoinflammatory Diseases. Front Immunol 10:2448. https:\/\/doi.org\/10.3389\/fimmu.2019.02448","journal-title":"Front Immunol"},{"key":"9042_CR168","unstructured":"A phase 2b pivotal study to evaluate the efficacy and safety of izokibep in subjects with moderate to severe hidradenitis suppurativa. Natl Libr Med. Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT05355805"},{"key":"9042_CR169","unstructured":"Announces izokibep achieves HiSCR100 responses at 12 weeks in moderate-to-severe hidradenitis suppurativa. ACELYRIN, Inc. Available from: https:\/\/www.prnewswire.com\/news-releases\/acelyrin-inc-announces-izokibep-achieves-hiscr100-responses-at-12-weeks-in-moderate-to-severe-hidradenitis-suppurativa-301775533.html"},{"key":"9042_CR170","unstructured":"Phase 2, randomised, parallelgroup,double-blind, placebo-controlled study of sonelokimab in patients with active moderate to severe hidradenitis suppurativa. Natl Libr Med. Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT05322473"}],"container-title":["Clinical Reviews in Allergy &amp; Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-025-09042-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12016-025-09042-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-025-09042-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T19:29:06Z","timestamp":1741807746000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12016-025-09042-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,12]]},"references-count":170,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["9042"],"URL":"https:\/\/doi.org\/10.1007\/s12016-025-09042-5","relation":{},"ISSN":["1559-0267"],"issn-type":[{"value":"1559-0267","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,12]]},"assertion":[{"value":"3 March 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that the research was conducted without any commercial or financial relationships that could be construed as a potential conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}],"article-number":"27"}}